Dose Determination and Efficacy Evaluation of the Gastrointestinal ReProgramming (GaRP) Dietary supplement in IBS patients: A Randomized, Double-blind, Placebo-controlled clinical trial


Oral and Gastrointestinal


Both males and females


From 18

to 65 years


Not yet recruiting

This study aims to test a potential new treatment for IBS using a Gastrointestinal Reprogramming Product (GaRP) that has been designed by Anatara to address the key underlying factors associated with chronic gastrointestinal conditions like IBS. 

GaRP is a multi-component, coated complementary medicine that has demonstrated safety and tolerability in Stage 1 of the trial. In Stage 2, the aim is to confirm efficacy of the dose identified in Stage 1.


Clinical Trial Site: Oztrials Clinical Research
Phone Number: 02 9719 3852 Email: Location: suite 1/56-56a Thompson Street, Drummoyne NSW, Australia

Studies Contact Form

  • Hidden

Approved By:              

Clinical Trial Registry Link: